Current research is increasingly focused on integrating metabolic therapies with molecular profiling, such as applying AMPK activators or metabolic diets in patients with obesity, insulin resistance, or specific mutations that confer metabolic vulnerabilities. This evidence concerns the gene PRKAA1 and obesity due to melanocortin 4 receptor deficiency.